RANI
Rani Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
High Gross Profit Margin
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RANI
Rani Therapeutics Holdings, Inc.
A clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs
Pharmaceutical
04/06/2021
07/30/2021
NASDAQ Stock Exchange
105
12-31
Common stock
2051 Ringwood Avenue, San Jose, California 95131
--
Rani Therapeutics Holdings, Inc., was incorporated in Delaware on April 6, 2021. The company is a clinical-stage biotherapeutic company advancing technology to facilitate the development of oral biologics, which the company believes has the potential to transform medicine and improve treatment outcomes for patients. The company developed RaniPill capsules, the company's novel, proprietary and patented platform technology designed to replace subcutaneous or intravenous biological agents with oral administration.
Company Financials
EPS
RANI has released its 2025 Q3 earnings. EPS was reported at -0.12, versus the expected -0.12, meeting expectations. The chart below visualizes how RANI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
